文献速递造血干细胞移植与细胞治疗

帕比司他预防急性移植物抗宿主病的2期试验

A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention.
PubMed 文献 · Blood Adv · 2021-01-01

这项2期试验在38例接受异基因造血干细胞移植的患者中,评估组蛋白去乙酰化酶抑制剂帕比司他(PANO)联合他克莫司和西罗莫司预防急性GVHD的效果。第100天II-IV级aGVHD累积发生率为18.4%(90%CI 9.4%-29.9%),达到主要研究终点;1年总生存率为89.5%。

要点

  • PANO联合他克莫司和西罗莫司达到aGVHD预防的主要终点。
  • 第100天II-IV级aGVHD累积发生率为18.4%(90%CI 9.4%-29.9%)。
  • 1年总生存率为89.5%,非复发死亡率为2.6%。

核心结论

  • PANO联合方案达到aGVHD预防的主要研究终点,值得进一步测试。

研究设计与样本

  • 2期试验纳入38例患者,中位年龄58岁(范围19-72岁)。
  • 供者均为HLA 8/8相合,亲缘13例、非亲缘25例,使用G-CSF动员的外周血干细胞。
  • 预处理为清髓性18例、减低强度20例;疾病包括AML 17例、MDS 13例、其他恶性肿瘤8例。
  • PANO自第-5天起口服5 mg每周3次、共26周,第-3天起加他克莫司、第-1天起加西罗莫司。

主要发现

  • 第100天II-IV级aGVHD累积发生率为18.4%(90%CI 9.4%-29.9%)。
  • 1年慢性GVHD累积发生率为31.6%(90%CI 19.5%-44.3%)。
  • 1年总生存率为89.5%(90%CI 81.6%-98.0%),无复发生存率为78.9%(90%CI 68.8%-90.6%)。
  • 1年非复发死亡率为2.6%(90%CI 0.3%-9.9%),GVHD无复发生存率为60.5%(90%CI 48.8%-75.1%)。
  • PANO相关不良事件包括血小板减少5例、白细胞减少6例、胃肠道毒性3例、皮疹4例、肾衰竭/外周水肿1例、眶周水肿1例。

临床怎么用

  • PANO联合他克莫司和西罗莫司可作为aGVHD预防的候选方案,尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory properties of histone deacetylase inhibitors represent a reasonable approach for acute graft-versus-host disease (aGVHD) prevention. We report a phase 2 trial evaluating panobinostat (PANO) administered over 26 weeks, starting on day -5 (5 mg orally 3 times a week) with tacrolimus initiated on day -3 plus sirolimus on day -1, with a median patient age of 58 years (range, 19-72 years) (n = 38). Donor source consisted of HLA 8/8-matched donors, related (n = 13) or unrelated (n = 25), using granulocyte colony-stimulating factor-stimulated peripheral blood stem cells. Myeloablative (n = 18) or reduced-intensity (n = 20) conditioning regimens were used for patients with acute myeloid leukemia (n = 17), myelodysplastic syndrome (n = 13), or other malignancies (n = 8). The cumulative incidence of aGVHD II-IV by day 100 was 18.4% (90% confidence interval [CI], 9.4% to 29.9%). Cumulative incidence of chronic GVHD at 1 year was 31.6% (90% CI, 19.5% to 44.3%). Adverse events related to PANO were thrombocytopenia (n = 5), leukopenia (n = 6), gastrointestinal toxicity (n = 3), rash (n = 4), renal failure/peripheral edema (n = 1), and periorbital edema (n = 1). At 1 year, overall survival was 89.5% (90% CI, 81.6% to 98.0%), relapse-free survival was 78.9% (90% CI, 68.8% to 90.6%), nonrelapse mortality was 2.6% (90% CI, 0.3% to 9.9%), and GVHD relapse-free survival was 60.5% (90% CI, 48.8% to 75.1%). PANO hits histone 3 as early as day 15 in CD8, CD4 and T regs. In conclusion, PANO combination met the primary study end point for aGVHD prevention and warrants further testing. This trial was registered at www.clinicaltrials.gov as #NCT02588339.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Perez L, Fernandez H, Kharfan-Dabaja M, et al. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021. PMID: 34242388. doi:10.1182/bloodadvances.2021004225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。